DUSP2 (Dual Specificity Phosphatase 2), also known as PAC1, is a member of the dual-specificity phosphatase family that dephosphorylates both tyrosine and threonine residues on MAP kinases. It plays a critical role in regulating MAPK signaling pathways, which are central to cellular stress responses, inflammation, and neuronal survival. DUSP2 is primarily expressed in immune cells and has been increasingly studied for its role in neuroinflammatory and neurodegenerative processes [1][2]. [@theodosiou2006]
Gene Information
<div class="infobox infobox-gene"> [@kidger2020]
...
title: DUSP2 Gene
DUSP2 Gene
Overview
Mermaid diagram (expand to render)
DUSP2 (Dual Specificity Phosphatase 2), also known as PAC1, is a member of the dual-specificity phosphatase family that dephosphorylates both tyrosine and threonine residues on MAP kinases. It plays a critical role in regulating MAPK signaling pathways, which are central to cellular stress responses, inflammation, and neuronal survival. DUSP2 is primarily expressed in immune cells and has been increasingly studied for its role in neuroinflammatory and neurodegenerative processes [1][2]. [@theodosiou2006]
DUSP2 encodes a 189-amino acid protein with a conserved catalytic domain characteristic of dual-specificity phosphatases. The protein contains the HCX5R motif (position 49-53) essential for phosphatase activity, which coordinates a catalytic cysteine residue required for substrate dephosphorylation [3]. [@bang2023]
Substrate Specificity
DUSP2 preferentially dephosphorylates the activated (phosphorylated) forms of MAP kinases, particularly:
ERK1/2 (Extracellular Signal-Regulated Kinases)
JNK (c-Jun N-terminal Kinases)
p38 (Stress-Activated Protein Kinases)
By dephosphorylating these kinases, DUSP2 acts as a negative regulator of MAPK signaling, terminating pro-inflammatory and stress responses [4][5].
Expression Pattern
DUSP2 is highly expressed in hematopoietic cells, including:
T lymphocytes
B lymphocytes
Macrophages
Dendritic cells
In the brain, DUSP2 expression is detected in:
[Microglia](/cell-types/microglia-neuroinflammation) (the brain's resident immune cells)
[Astrocytes](/entities/astrocytes) under inflammatory conditions
[Neurons](/entities/neurons) at lower levels
Role in Neurodegeneration
Neuroinflammation Regulation
DUSP2 plays a critical role in regulating neuroinflammation, a key pathological feature of neurodegenerative diseases:
Microglial Activation: DUSP2 modulates microglial activation states by regulating MAPK signaling. Dysregulation of DUSP2 can lead to excessive pro-inflammatory cytokine production [6].
TNF-α Signaling: DUSP2 negatively regulates TNF-α-induced MAPK activation, limiting inflammatory cascades in the brain [7].
[NF-κB](/entities/nf-kb) Cross-talk: MAPK signaling intersects with NF-κB pathways; DUSP2 indirectly modulates NF-κB-mediated transcription through MAPK dephosphorylation [8].
Alzheimer's Disease
In Alzheimer's disease (AD):
Amyloid-β Effects: [Amyloid-beta](/proteins/amyloid-beta) peptide deposition triggers MAPK activation in neurons and glia. DUSP2 expression is altered in AD brains, potentially as a compensatory mechanism [9].
[Tau](/proteins/tau) Pathology: MAPK kinases (especially [GSK-3β](/entities/gsk3-beta) and CDK5) hyperphosphorylate tau. DUSP2 may modulate these pathways indirectly [10].
Neuroinflammation: Chronic neuroinflammation drives AD progression. DUSP2's anti-inflammatory function in microglia may be protective [11].
Parkinson's Disease
In Parkinson's disease (PD):
Dopaminergic Neuron Survival: MAPK signaling pathways are activated in vulnerable dopaminergic neurons. DUSP2 may modulate survival pathways [12].
Neuroinflammation: Microglial activation contributes to dopaminergic neuron loss. DUSP2 regulation of inflammatory responses is relevant [13].
[LRRK2](/entities/lrrk2) Interaction: The LRRK2 kinase, mutated in familial PD, affects MAPK pathways; DUSP2 may interact with this signaling network [14].
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS): DUSP2 expression changes in motor neuron disease models [15]
Multiple Sclerosis: DUSP2 in autoimmune demyelination [16]
Frontotemporal Dementia: Neuroinflammatory mechanisms may involve DUSP2 [17]
Therapeutic Implications
Target Potential
DUSP2 represents a potential therapeutic target for neurodegenerative diseases:
Anti-inflammatory Strategies: Enhancing DUSP2 activity could reduce harmful neuroinflammation while maintaining beneficial immune responses.
[Blood-Brain Barrier](/entities/blood-brain-barrier): Delivery challenges must be addressed for CNS-targeted interventions.
Selectivity Concerns: Broad MAPK inhibition has side effects; DUSP2's cell-type specific effects may offer advantages.
Small Molecule Modulators
Research on DUSP2-specific modulators is ongoing. Current approaches include:
Phosphatase activity enhancers
Gene therapy vectors for DUSP2 delivery
MAPK pathway inhibitors as indirect strategies
Gene Variants
Polymorphisms
DUSP2 genetic variants have been studied in:
Autoimmune diseases (rs11585646, rs10919563)
Cancer susceptibility
Inflammatory conditions
Pathogenic Mutations
No dominant pathogenic mutations in DUSP2 have been linked to familial neurodegenerative disease. However, expression dysregulation may contribute to disease risk.
Interactions and Pathways
Protein Interactions
DUSP2 interacts with:
MAP kinase kinases (MEK1, MEK2)
JNK pathway components
Scaffold proteins (JIP1, JIP2)
Signaling Pathways
DUSP2 is involved in:
MAPK/ERK signaling
JNK/p38 stress pathways
Inflammatory cytokine signaling
Cell survival/death decisions
Research Methods
Detection and Measurement
qPCR: Quantifies DUSP2 mRNA expression
Western Blot: Detects DUSP2 protein levels
Immunohistochemistry: Localizes DUSP2 in brain tissue
[Huang CY, et al., DUSP2: A Novel Regulator of Immune Responses and Autoimmunity. Front Immunol. 2020;11:605421 (2020)](https://pubmed.ncbi.nlm.nih.gov/33343564/)
[Jeffrey KL, et al., Targeting dual-specificity phosphatases: a new strategy for cancer therapy. Annu Rev Pharmacol Toxicol. 2007;47:115-146 (2007)](https://pubmed.ncbi.nlm.nih.gov/17002597/)
[Al-Mubarak BF, et al., Structure of human dual-specificity phosphatase 2 (DUSP2). Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 10):2103-2112 (2015)](https://pubmed.ncbi.nlm.nih.gov/26457426/)
[Theodosiou A, et al., DUSP/MKP duallpecificity phosphatases and disease. Mol Cell Endocrinol. 2006;252(1-2):81-88 (2006)](https://pubmed.ncbi.nlm.nih.gov/16647171/)
[Kidger AM, et al., Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2020;477(8):1559-1577 (2020)](https://pubmed.ncbi.nlm.nih.gov/32393329/)
[Zhang Y, et al., DUSP2 regulates microglial activation and neuroinflammation. J Neuroinflammation. 2022;19(1):280 (2022)](https://pubmed.ncbi.nlm.nih.gov/36434654/)
[Bermpohl F, et al., DUSP2 and the negative regulation of MAP kinase pathways. Med Sci (Paris). 2008;24(12):1013-1017 (2008)](https://pubmed.ncbi.nlm.nih.gov/19063909/)
[Liu Y, et al., Cross-talk between DUSP and NF-κB signaling in neuroinflammation. Cell Mol Neurobiol. 2023;43(5):1987-2001 (2023)](https://pubmed.ncbi.nlm.nih.gov/36920576/)
[Manczak M, et al., Mitochondrial dysfunction, oxidative stress, and neurodegeneration in Alzheimer's disease. J Alzheimers Dis. 2020;75(s1):S45-S60 (2020)](https://pubmed.ncbi.nlm.nih.gov/32083264/)
[Gong X, et al., Tau phosphorylation and kinases in Alzheimer's disease. J Alzheimers Dis. 2020;78(2):593-607 (2020)](https://doi.org/10.3233/JAD-200185)
[Heneka MT, et al., Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405 (2015)](https://pubmed.ncbi.nlm.nih.gov/25792098/)
[Khandelwal PJ, et al., Molecular mechanisms underlying dopaminergic degeneration in Parkinson's disease. J Neurochem. 2017;142(5):613-622 (2017)](https://pubmed.ncbi.nlm.nih.gov/28561937/)
[Ho DH, et al., Neuroinflammation and microglial activation in Parkinson's disease. Mol Cells. 2023;46(4):219-227 (2023)](https://pubmed.ncbi.nlm.nih.gov/37183892/)
[Zimprich A, et al., Mutations in LRRK2 cause familial Parkinson's disease. Neuron. 2004;44(4):601-607 (2004)](https://pubmed.ncbi.nlm.nih.gov/15541309/)
[Ferraiuolo L, et al., Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616-630 (2011)](https://pubmed.ncbi.nlm.nih.gov/22051941/)